Stockalyze
Real reports

See what you'll get

These are real reports from our pipeline — five research angles, adversarial fact-checking, and cited sources. Your own requests look exactly like this.

INTU logo

INTU

Nov 20, 2026

Intuit Inc · today

Intuit's fiscal Q1 2027 beat estimates, but the outlook behind it got worse. Revenue was $4.354B, up 12% from $3.885B, against roughly $4.31B expected. GAAP diluted EPS was $2.59, up 63%, and non-GAAP EPS was $2.91, up 56% [2][8]. The beat was $0.21 against a $2.70 consensus or $0.45 against $2.46, depending on the benchmark [2][4]. Sources found no tariff refund, asset-sale gain or legal settlement in the quarter. About $30M of refund-transfer revenue moved from Q2 to Q3, which is a timing shift, not a one-time gain [2][8]. Growth was uneven. Global Business Solutions rose 15% to $3.1B, Consumer rose 7% to $958M (including $708M from Credit Karma) and Mailchimp fell 1% to $313M [5]. The stock fell about 9.8% after hours, from a $310.02 close to roughly $279.6. The guidance caused it: Q2 revenue growth of only 6-7% with TurboTax revenue down year over year, FY27 Consumer growth cut to 2-4% and Credit Karma cut to 3-7% [1][4][9]. Full-year revenue guidance is $23.081-$23.365B (8-9% growth), and non-GAAP EPS guidance of $22.88-$23.12 was reaffirmed [10][21]. The case for selling: core consumer and fintech growth is slowing, Mailchimp's roughly $313M a quarter will leave the revenue base once sold [10], the stock fell about 9.4% in two sessions before earnings with no identified catalyst [23], and the chart is weak. The case for holding: earnings per share are still growing and guidance was kept, cash returns are rising, and the multiple has already compressed a lot. On valuation, the shares trade at about 13.5x the FY27 non-GAAP EPS guidance midpoint at the $310 close and about 12x at the ~$280 after-hours price [21]. Cited multiples vary by source. Trailing P/E is 17.66x on StockAnalysis [20] and about 19.4x on WallStreetZen [12]. Forward P/E is 12.70x on StockAnalysis [20] and about 15x according to Wells Fargo, which also cites about 11.5x EV/FCF [12]. These levels are far below the premium the stock carried near its $682.27 52-week high. The 12-month price change is about -52.3%, with a 52-week range of $252.84-$682.27 [11][18]. Without a sourced 5-year multiple series or peer multiples, the comparison with history is only directional [12][21]. Capital returns are a support. Intuit bought back $1.5B of stock in Q1 (+73% YoY) and raised its quarterly dividend 15% to $1.38, an annualized yield of roughly 1.8% [13][17]. The planned Mailchimp sale to Bending Spoons (reported at about $3.68B, closing in early calendar 2027) earmarks the proceeds for extra FY27 buybacks [10][17]. Any gain on the sale will be a one-time item to strip out of later results [10][17]. Free cash flow is cited at about $7.7B, and the balance sheet looks roughly net-debt-neutral, though this is low-confidence aggregator data [24]. Wall Street is split and leaning cautious. S&P Global data on StockAnalysis shows 34 analysts with a consensus 'Buy' (15 Strong Buy, 5 Buy, 12 Hold, 1 Sell, 1 Strong Sell), so about 41% rate the stock Hold or worse [14]. MarketBeat labels the consensus 'Hold' [14]. Average targets run from about $380 to $430 depending on the aggregator: StockAnalysis $408.86 (range $290-$732), ChartMill $418.76, MarketBeat $417.90, WallStreetZen $379.62, Getquin $394.85 and Benzinga $430.24 [6][7]. The targets most recently set by large banks sit much closer to the price. Morgan Stanley has a Hold at $315, Wells Fargo an Equal Weight raised to $330 and Barclays an Overweight at $408 (all November 17-18). Piper Sandler has a Sell at $290, TD Cowen a Hold at $350 and BMO a Buy at $412, and Goldman Sachs has been reported at Sell with a $304 target [15][16]. Stifel and Goldman downgraded the stock around May-June 2026 [6]. The technical setup is bearish. At the $310.02 close the stock sat below its 50-day average (~$317.9) and its 200-day average (~$348-$349), with the 50-day below the 200-day [3]. RSI(14) was 38.59, weak but not yet oversold, and the after-hours drop will likely push it toward 30 [22]. Possible support is the $252.84 52-week low. Resistance sits near $318, $345.56 and $348-$349 [19]. Things to watch next: the Q2 print against the 6-7% guide and any further cuts to Consumer or Credit Karma, Mailchimp closing terms in an 8-K, how fast extra buybacks start, and how analysts revise targets after the guide [4][10][16][17].

ANT logo

ANT

Nov 19, 2026

Anthropic, PBC · yesterday

Anthropic (ANT) begins trading on the Nasdaq Global Select Market on 2026-11-19 with no price history [2]. The IPO priced at $83, above the marketed $70–$78 range, on 980 million Class A shares, raising about $81.3B in what is reportedly the largest IPO on record [3]. Pricing coverage puts the fully diluted value at about $1.5T [4][18]. The book was reportedly almost 7 times oversubscribed [15][17]. Growth is the core of the bull case. Q3 2026 revenue was about $16.96B, up from about $11.6B in Q2, for $33.24B over nine months [5]. That compares with $4.6B for all of 2025 [6], and H1 2026 revenue of $16.3B was about 14 times H1 2025's $1.16B [5][6]. Customers paying over $100K a year rose to 11,900 from 950 a year earlier, and revenue per dollar of compute rose from 0.69 in Q4 2025 to 2.08 in Q2 2026 [15]. The company also produces cash: H1 2026 free cash flow was about $3.45B ($3.93B operating cash flow less $482M capex), and nine-month operating cash flow was about $6.6B [1]. Mid-year cash and short-term investments were $131.7B, before the $81.3B IPO and a separate $26B private placement with AMD, Broadcom, Google, Micron, Microsoft, Nvidia and TSMC Partners [1]. GAAP results need heavy normalization before they mean much. The H1 2026 GAAP net loss of $80.7B includes $72.4B of non-cash fair-value changes on convertible notes, derivatives and SAFEs [11][12]. The nine-month net loss of about $104B includes a $94.32B fair-value charge [13]. These capital-structure items should largely go away once the instruments convert at listing [11]. On operations, Anthropic earned its first operating profit, $974M, in Q2 2026, then swung to a Q3 operating loss [7][13]. Sources disagree on that loss: Yahoo reports $536M [7] and sec-api.io reports about $567M [13]. The company blames a $5B charge for short-term compute commitments and $2B of non-cash donation-matching charges [7]. Excluding them, Q3 would show an operating profit of several billion dollars [7]. A skeptic would answer that compute charges may recur in a compute-heavy business, so the add-back is debatable [7]. The nine-month operating loss was $1.3B, versus $5.2B a year earlier [7]. Fortune reports adjusted H1 operating income of $1.62B, a 10% margin [13]. Valuation is the main tension for anyone weighing whether to hold or sell. At about $1.5T, ANT trades at roughly 22 times annualized Q3 revenue (about $68B) [9][20] and about 46 times annualized H1 revenue [18]. It pays no dividend, and trailing P/E is not meaningful [9]. The private rounds valued it at $183B in September 2025 and $965B in May 2026 [20]. There is no 5-year history or public peer multiple to compare against, and the closest rival, OpenAI, is private [9][20]. The bear case centers on compute obligations, concentration and dilution. The amended S-1 discloses $895.4B of total committed spend: $69.8B due within 12 months and about $447.5B before 2030-12-31 [8]. The original S-1 had listed $657B of compute commitments, $498B of them (76%) noncancelable, implying about $70B a year [14]. Nearly a quarter of revenue comes from two customers [21]. Risk factors cite a February 2026 federal order to stop using Anthropic's models and June 2026 export restrictions that took two models offline [21]. The board can issue an additional 2% of shares to the Anthropic Public Benefit Fund each time the stock rises 50% above a benchmark [15]. No bank has published a rating or price target [16][19]. Goldman Sachs and Morgan Stanley lead a 22-bank syndicate with J.P. Morgan next [16][19], and syndicate coverage would typically start after the quiet period, around mid-December 2026; that date is an inference, not a reported fact [16]. Technically, moving averages, RSI and support/resistance cannot yet be calculated [2]. The $83 offer price is the only reference level, a possible support if the stock holds above it or resistance if it breaks below [17]. Near-term catalysts are the opening trade, initiation of coverage once the quiet period ends [16], the first public quarterly report, and lock-up expiry, whose terms were not found [21]. The evidence supports both readings: exceptional growth and cash generation on one side, and a premium multiple, large fixed compute commitments and a recent swing back to an operating loss on the other.

SLS logo

SLS

Nov 18, 2026

Sellas Life Sciences Group Inc · 2 days ago

SELLAS (SLS) is a pre-revenue biotech whose valuation was reset by one binary event. On November 17, 2026 the stock closed at $19.15, up 156.36% in one session from about $7.47. The move followed the company's announcement of positive topline Phase 3 REGAL data for galinpepimut-S (GPS) in AML, which it described as a statistically significant and clinically meaningful improvement in overall survival [9]. The readout came after a volatile run-up. Shares fell 14.71% to $10.38 on October 28, when the trial reached its 80th event, the trigger for the final analysis [1][14]. That event came about 10 months later than planned, which TIKR said could reflect either a GPS benefit or a stronger-than-assumed control arm [8]. The stock then drifted to $8.55–$9.14 in early November and to $7.47 by November 16 [1][14]. Fundamentals are thin. There was no Q3 2026 revenue. The net loss was $10.1M ($0.05/share), versus $6.8M a year earlier. R&D rose to $7.0M from $4.2M, partly on BLA preparation, and G&A rose to $4.3M from $2.9M, mainly from non-cash stock-based compensation. The release identifies no one-time items to normalize [3][7][13]. The balance sheet is clean but small relative to the valuation: $134.7M of cash, no debt and about $9.3M of liabilities at September 30 [4]. At about $3.90B of market cap and about $3.77B of enterprise value [22], P/E and EV/EBITDA are not meaningful. Price-to-book is roughly 30x [15]. Market cap sits far above the company's own 5-year history, which ranges from $34.0M at end-2023 to $537.0M at end-2025 [16]. No peer multiples were verified, so no peer comparison is made [16][21]. The constructive case starts with the trial result itself: a statistically significant overall-survival result in a pivotal trial, as the company describes it [9]. An FDA filing is targeted for 1H 2027, and a second asset, SLS009 (tambiciclib), adds further catalysts. Its newly diagnosed AML Phase 2 data are due in Q4 2026 and relapsed/refractory data will be presented at ASH on December 12–15, 2026. Earlier SLS009 data showed a 54% response rate in monocytic AML and 57% in TP53-mutated AML [8][21]. Sell-side targets are mostly above the current price. Maxim raised its target to $40 from $30 on November 17 and kept its Buy rating [18]. Finviz shows 4 Buy ratings and a $37.50 average target [21]. The pre-readout Maxim/Alliance average of $32.50 was about 70% above the $19.15 close [17]. The cautionary case starts with dilution and how extended the stock is. A proposed $150.0M public offering, announced at 4:01 PM ET on November 17, pushed shares to about $17.07–$17.10 after hours, down about 10.7% [10][22]. That comes on top of 33% share-count growth year to date, to 203.5M shares [7]. TIKR had warned that a win could require equity funding for a BLA and launch [8]. On technicals, RSI(14) is about 76.6–76.7, overbought [2]. The stock trades about 74% above its 50-day average (~$11.01) and about 116% above its 200-day average (~$8.88) [11]. Returns are about +1,258% over 12 months and about +408% year to date [20]. Short interest is 28.34% of float [21]. Derived levels, not published studies, put resistance near the new $24.89 52-week high. Possible support sits at the prior $15.88 high, then ~$11.01, then ~$7.47 [12]. Analyst coverage is thin and comes only from small-cap brokers. No major bank coverage was found [19]. Aggregator consensus figures conflict, ranging from a stale $6.50 to $40 [6][23][24]. Forward risks include the full data details, the FDA review, how the offering is priced, commercialization costs and the SLS009 readouts [8][10][21].

INTC logo

INTC

Nov 17, 2026

Intel Corp · 3 days ago

Intel's Q3 2026 results were mixed once one-time items are normalized. Revenue rose 21% year over year to $16.51B from $13.65B. Data Center and AI drove the growth, up 78% to $7.3B, while Client Computing and Physical AI fell 5% to $8.1B [2][8]. Non-GAAP EPS was $0.52, up from $0.23 and above Intel's own $0.38 guidance, though revenue came in slightly below the $16.56B consensus MarketBeat cites [8]. GAAP EPS fell to $0.60 from $0.90, but that comparison is distorted by one-time items on both sides. The prior-year quarter included a $5,452M divestiture gain, mostly from Altera. Q3 2026 GAAP results were lifted by an Escrowed Shares mark-to-market gain and $330M of net equity-investment gains, which is why GAAP EPS was above non-GAAP [13][18]. Non-GAAP EPS of $0.52 is the better measure of operating results. Over nine months, a $12,614M Escrowed Shares loss and $3,969M of restructuring produced an $11,609M net loss [13]. The outlook is the main problem: Q4 guidance calls for $15.0B to $16.0B of revenue, a 38.0% non-GAAP gross margin (down from 44.1%) and $0.25 of non-GAAP EPS (down from $0.52) [9]. The balance sheet is a support. At quarter end Intel held about $54.0B of cash and investments against about $50.1B of debt, a small net cash position. Q3 operating cash flow was $5.08B, capex $4.22B and adjusted free cash flow $1.64B. However, shares outstanding rose to 5,310M from 4,994M after a $22.6B net equity offering, which dilutes per-share figures [5]. At $55.47 (market cap about $294.8B, EV about $290.6B), trailing P/E is not meaningful because trailing earnings are negative. Forward P/E is 39.85x, P/B 2.56x, P/S 4.92x and EV/EBITDA 15.18x [3]. Against AMD, Intel trades at a slight premium on forward P/E (AMD 33.50x) but at a deep discount on EV/EBITDA (AMD 73.63x), P/B (12.09x) and P/S (18.20x). AMD's TTM free cash flow of $7.06B is also well above Intel's $3.77B [4]. Against its own history, EV/EBITDA is close to FY2025's 15.68x but well above FY2021-FY2022 (6.27x-7.37x). P/B is the highest since at least FY2021, partly because of the equity raise. Forward P/E is below FY2025's 85.44x but well above FY2021-FY2022 (14.22x-18.19x) [21]. Intel pays no dividend [14]. The Wall Street view has moved to cautious. The consensus is Hold: of 49 analysts, 12 rate it Strong Buy, 2 Buy, 34 Hold, 0 Sell and 1 Strong Sell, and other aggregators also show Hold [1]. Ratings and targets were cut widely after Q3. Bank of America downgraded to Neutral and cut its target from $145 to $100, then to $80 [15]. Citi kept its Buy rating but cut its target from $130 to $100 [7]. Barclays and RBC both rate Intel Hold with $75 targets [7]. Roth downgraded to Neutral with a cut from $120 to $70, Freedom Broker moved to Hold at $90, and Susquehanna cut to $105 and later reportedly to $75 [16]. The average target of $90.65 (median $86, range $63-$160) sits well above the price, and the stock is about 12% below even the lowest target. This suggests many targets have not caught up with the sell-off [6]. The cautious case rests on several points: the sharp Q4 margin and EPS step-down [9], a reported two-week Kiryat Gat fab shutdown estimated to cost about $300M of Q4 revenue and about 200bp of gross margin, management's expectation of double-digit PC market contraction through mid-2027, a new securities class action naming the CEO and CFO [20], share dilution [5], and a forward P/E above AMD's [4]. The more patient case points to strong Data Center and AI growth [2], net cash [5], EV/EBITDA far below AMD's [4], and price targets that are still above the price even after the cuts [6][7][15]. Technically, the stock is in a clear downtrend. The day after earnings it reportedly fell about 28.6% to roughly $65.76, described as its worst day since 1974, and it kept falling to $55.47 by Nov 16 [10]. As of Nov 13 it was down 33.60% over one month [17]. The price is far below the 50-day moving average ($94.17) and the 200-day ($87.44). The 14-day RSI is 29.86 and the 5-year beta is 2.43 [19]. Other aggregators put RSI between about 28.8 and 32.42, and MACD (12,26,9) is at -0.260, a sell signal [12]. TipRanks' moving-average tally is 11 Bearish to 1 Bullish [22]. Support is cited in the $52.25 to $54.00 zone [23]. The 52-week range is $32.89 to $142.35, and the stock is still up roughly 47.6% to 56% over a year, depending on the source [11][19]. Key forward risks are delivery against the weak Q4 guide [9], the fab-outage, PC-demand and litigation headwinds [20], and high volatility [19]. Possible catalysts are continued Data Center and AI momentum [2], a reset of analyst targets toward the current price [6], and the oversold readings that Investtech notes can come before a technical rebound [12]. Taken together, the evidence shows real revenue growth and a solid balance sheet set against a sharp margin reset and weak near-term sentiment. Readers should weigh these themselves; this report makes no recommendation.

ASML logo

ASML

Nov 16, 2026

ASML Holding · 4 days ago

Fundamentally, ASML's latest quarter was strong, but the headline overstates it. Q3 2026 net sales were €11,662 million, up from €9,326 million in Q2. Gross margin was 57.5%, net income €4,960 million and basic EPS €12.95, on 113 new and 8 used lithography systems and €3,289 million of Installed Base Management sales [1]. Management guided Q4 net sales to €14.2–15.2 billion at about 57% gross margin and full-year 2026 to €44–45 billion at about 56%. The CEO said planned 2027–2028 supply 'will not fully meet the demand of our customers', and ASML plans to raise low-NA EUV and DUV immersion capacity by 30% in 2027 [2]. A secondary source could not match the Q4 guide to the release [19], but the primary 6-K contains it [2]. The beat needs normalizing. Q3 net income included a gain of roughly €500 million tied to ASML's Mistral AI stake, about 10% of net income [21]. Operating income was about €5.2 billion, so the jump in basic EPS from €7.59 in Q2 to €12.95 in Q3 likely overstates core earnings growth [15]. The balance sheet is net cash. Trailing free cash flow was $23.34 billion against $2.24 billion of total debt. Cash and short-term investments were €12,735 million at quarter-end, after about €4.1 billion of Q3 buybacks [18]. An interim dividend of €1.88 was paid on November 4 (trailing yield about 0.53%) [8]. ASML does not report quarterly bookings, so customer interest in 2029–2030 orders is not firm backlog [2][19]. Valuation and the Wall Street view. At the $1,495.16 close on November 13, ASML traded at 38.77x trailing and 23.44x forward earnings, 29.99x EV/EBITDA and 22.47x book, with a market cap of $564.94 billion [16]. It trades at a premium to Applied Materials on every multiple compared: 29.36x trailing, 19.31x forward, 24.43x EV/EBITDA and 11.25x book, with similar dividend yields (0.53% vs 0.57%) [17]. Against its own history, the trailing P/E and EV/EBITDA sit at the top of the FY2022–FY2025 range (34.3–37.0x and 27.0–28.8x) but below the FY2021 peak of 48.8x and 41.0x, while P/B is above FY2023–FY2025 levels of 14.4–20.0x [22]. MarketScreener's estimates put the P/E at 32.1x for 2026E and 23.5x for 2027E, but that page may be stale [16]. The sell-side remains constructive. MarketBeat shows a 'Moderate Buy' consensus across 24 ratings (2 Strong Buy, 17 Buy, 2 Hold, 3 Sell) with a $2,204.71 average target [3]. That is about 44% above the November 11 mid-day price of $1,534.42 [9]. StockAnalysis puts the average near $2,138, and target lows run $1,415–$1,450 [14]. Named bank targets include Bernstein at $2,623, Wells Fargo at $2,500, JPMorgan at $2,350 (cut from $2,400 on October 15), and RBC and Argus at $2,100 each [10]. Activity in the last 90 days was mostly reiterations plus JPMorgan's $50 trim, with no new rating changes found from Goldman Sachs, Morgan Stanley, BofA or Barclays [11]. A large gap between price and target usually means analysts have not yet caught up with a falling price, not that upside is confirmed [9]. Technical posture and the balanced case. The stock's near-term trend is weak. It sits about 25% below its 52-week high of $1,999.96, though it is up 44.14% over 52 weeks from a low of $946.11 [5]. The price is below both the 50-day average (about $1,660) and the 200-day (about $1,602). The 50-day is still above the 200-day, so the long-term structure holds for now while the near-term trend has broken down [6][4]. The shares fell about 13.6% over 30 days into late October [7]. They dropped 6.67% on November 5 on export-control worries, customer capex caution and higher bond yields, then rose 6.12% on November 9 in an AI rally [7]. RSI(14) has recovered to about 42 from oversold readings of about 27–29 around November 4–5 [12]. Near-term support is around $1,355. Resistance sits at the 200-day and 50-day averages (about $1,600 and $1,660) and at the roughly $2,000 52-week high [13]. The case for caution: a premium multiple against both its peer and its own recent history [17][22], a broken short-term trend [6], a one-time gain inflating Q3 earnings [21], and risks from export controls, tariffs and the gap between stated demand and firm orders [23][7]. The case for patience: confirmed Q4 and full-year guidance, a supply-constrained outlook for 2027–28 with planned capacity growth [2], strong cash generation and buybacks [18], a forward P/E well below the trailing one [16], and catalysts named in the coverage, including AI-driven memory and logic spending and High-NA EUV adoption [23].

SPCX logo

SPCX

Nov 15, 2026

Space Exploration Technologies Corp · 5 days ago

Fundamentals and valuation: SPCX has posted very fast growth, but its profits are still thin when one-time items are taken out, and its valuation is high. Q3 2026 revenue was reported at $14.58B, up 161% year over year, against a $12.59B consensus. EPS was $0.35 against expectations of $0.10-$0.11 [4][13]. This followed a Q2 with $7.81B of revenue and a $541M net loss [4]. The headline Q3 net income of $4.4B needs adjusting. About $2.3B of it came from non-operating and tax items: $0.9B of interest income, $1.0B of other income and a $0.4B tax benefit. Operating income of $2.8B (a 19.1% margin) is the cleaner measure, so roughly half of reported profit did not come from operations [18]. On a trailing basis, net margin is still negative (-8.6%), so P/E is not meaningful. The shares trade at about 59x TTM revenue of $32.04B and an estimated ~133x EV/EBITDA [17], at a market cap of about $1.89T [11][12]. Other snapshots put the multiple at about 63x trailing sales in late August [4] and about 45x estimated 2026 sales in July [11]. Cash flow is the central tension. TTM free cash flow was about -$39.2B on $55.0B of capex, $19.6B of it in Q3 alone. That is cushioned by about $89.9B of cash and securities, or about $51.0B of net cash [14]. Looking ahead, Morgan Stanley does not expect positive FCF before 2035 as capex rises toward $300B a year by 2031, and Goldman estimates about $270B of debt will need to be raised over 2026-2030 [15]. Reported guidance of $100B annualized revenue by end-2026 and $33-37B in Q1 2027 [21] would be a major catalyst if met, but it is a large execution step up from Q3 and has only low-confidence sourcing. The Wall Street view: sell-side sentiment is clearly positive but the targets are very far apart. The S&P Global panel of 40 analysts shows 24 Strong Buy, 8 Buy, 6 Hold, 0 Sell and 2 Strong Sell [9]. The average target is $256.41 and the median $245, implying about 84% and 76% upside, within a range of $70 to $800 [2]. Recent actions are mostly reiterations rather than upgrades: Deutsche Bank at $250, Stifel at $190, and Bank of America kept its Buy without a published target [10]. Goldman raised its target to $230 from $205 [3]. Post-Q3 reports also have TD Cowen at $224 and Morgan Stanley at $300, and say JPMorgan raised to $500 from $240 [8]. The JPMorgan figure itself is unconfirmed [3]. The bearish minority includes Phillip Securities at Sell/$75 (about 46% below the price) and DZ Bank's August cut to Sell [16]. The tension is that the stock closed at $139.11 on November 13. That is only about 3.0% above the $135 IPO price and about 38% below the $225.64 all-time high [1]. It is also roughly flat against the late-August close of $137.95, even though targets were raised [5]. The market has not adopted the sell-side's optimism. Technical posture and forward risks: the price is neutral to weak, and share supply weighs heavily. SPCX sits just above its 50-day SMA ($137.80) and just below its 50-day EMA ($139.93). It is about 6% below a 200-period SMA of $147.34, with RSI(14) at 46.1, and Investing.com's moving-average summary reads 'Strong Sell' [19]. The $135 IPO price has acted as a pivot. Shares dipped to about $123.62 on November 5 and then recovered to $139-$142 [6]. Resistance is near $171.92 (the October 6 high) and $225.64, and support is at the $104.83 52-week low [6]. The price is also down from $147.49 on October 23 [12]. The main near-term event is the December 8 lockup expiry of up to about 797.6M shares (over $110B), following earlier tranches of 911.5M, 319M and up to 1.3B shares [7]. Option-implied volatility near 59% compares with about 69% realized [11], and beta is 3.18 [12]. A political catalyst also hangs over the stock. The roughly 13% two-session drop after the November 3 midterms was tied to a Texas governor-elect who campaigned on pausing new data-center construction, which bears on SpaceX's AI-infrastructure plans [20]. Bulls point to the Q3 beat, AI revenue above $7.5B [4], strong analyst support and a large net cash position. Bears point to extreme multiples, deeply negative FCF with large future funding needs, earnings boosted by non-operating items, and heavy pending supply. The evidence supports neither case decisively, and the reader should weigh these factors themselves.

NVDA logo

NVDA

Nov 14, 2026

NVIDIA Corp · 6 days ago

NVDA's latest reported fundamentals remain very strong, even with the stock in a sharp drawdown. In fiscal Q2 FY2027 (quarter ended July 26, 2026), revenue was $96.2B, up 106% year over year. Data Center revenue was $89.0B, up 117%, and gross margin was 75.0% [1][10]. One item needs normalizing: GAAP diluted EPS of $2.46 was above non-GAAP EPS of $2.22, largely because of about $7.8B of pre-tax gains on equity investments. That gain is non-operating, so $2.22 is the cleaner measure of operating earnings, still up about 120% [1][10]. Cash generation is large: trailing-twelve-month free cash flow is $127.01B, with about $23.61B of net cash ($62.47B cash against $38.86B debt) [19]. There are cash-quality warnings, though. Q2 free cash flow of $21.3B grew about 59% while revenue grew 106% [10], days-sales-outstanding has risen to 60, and about $50B has been invested in frontier AI labs [19]. The annual dividend is listed at $1.00 per share (0.61% yield) [18], which is negligible as a valuation support. On valuation, multiples have compressed sharply. At about $163 the stock trades at roughly 20.6x trailing earnings, 13.5x forward earnings, 17.5x book and 19.3x EV/EBITDA [11]. One outlet puts it at about 10.7x consensus FY2028 EPS of $15.75, and cites FactSet's next-twelve-month P/E of about 11.7x as the lowest since October 2011 [13]. For comparison, the S&P 500 is at roughly 18.7–20x, Broadcom about 19x and AMD between 27x and 32x depending on the source [13][21]. The case for holding or for the market having overshot rests on several points. The low multiple sits against guidance for further growth: Q3 revenue guidance is $108.0B ±2% ($105.84–$110.16B) at a 74.0% ±50bp gross margin, and that guidance excludes China data-center compute sales [1][2]. Management has also pointed to about 70% revenue growth in FY2028 and a Vera Rubin product ramp [5]. Sell-side sentiment is still overwhelmingly positive. Aggregators count roughly 59 Buy or Strong Buy ratings against 3 Hold and 1 Sell, with about 95% rated Buy [4][15]. Average targets range from about $271.64 to $326.92 depending on the aggregator and date, about $285–$290 on the main ones, which implies roughly 75–80% upside from the Nov 13 close [4][20]. Several large banks kept Buy-equivalent ratings with targets near $285–$300 [6]. Morgan Stanley described its removal of NVDA from its top-picks list as rule-driven rather than a change in its AI-buildout view [7]. Technically, the stock is deeply oversold. RSI(14) readings run from about 24.9 to 41.5 across sources [5][9], and the Nov 13 close of $162.85 is about 9% above the $148.81 52-week low, the nearest major support [16]. The case for selling or reducing exposure is also substantial. The stock closed at $162.85 on Nov 13, down 31.9% from its $239.24 record close on Oct 6 and down 21.2% since Nov 3 alone [8]. That drawdown erased close to $1.4T of market value [7]. Price sits about 20% below a 200-day average of roughly $204–$213, so the trend is clearly down [5][9]. Analyst momentum has turned negative. Baird downgraded to Neutral and cut its target 60%, from $500 to $200, citing limited 2027 supply visibility, hyperscaler capex growth slowing to about 40% or less, and uncertainty over CEO tenure [12]. Citi cut to $285 from $315 and Wells Fargo trimmed to $300 [6]. On Nov 12, BofA reportedly cut to $280 from $350 [20]. Over the past 90 days the major-bank actions were cuts or reiterations, not raises [6]. Governance risk is new and unresolved. Reuters-reported headlines about Jensen Huang led to an independent board investigation, a 4.3% one-day drop on Nov 9 (about $190B of market value) and a shareholder lawsuit [17]. Reports of his resignation are unconfirmed [17]. Other risks: gross margin is expected to bottom at 71–72% in Q4 on memory costs, along with supply constraints, China export rules and data-center power regulation [5][14]. A beta of 2.25 amplifies moves in either direction [5]. The next catalyst is Q3 FY2027 earnings on November 17, 2026, after the close [2][14]. Consensus of about $108.8–$109B revenue and $2.47–$2.49 EPS sits above the guidance midpoint [2][3][14]. That leaves little room for a disappointing result or outlook while the stock is technically weak, and a strong print could just as easily trigger a sharp rebound from oversold levels.

MSFT logo

MSFT

Nov 13, 2026

Microsoft Corporation · 7 days ago

Microsoft's latest quarter was strong, and much of the strength holds up after adjusting for non-operating items. Fiscal Q1 2027 revenue was $92.3B, up 19% and ahead of a consensus near $90.75B [1][6]. Azure grew 48% to $33.17B, faster than the 42% of the prior quarter [6]. One adjustment matters: GAAP diluted EPS rose 32% to $4.92, but that figure includes Microsoft's share of OpenAI investment results, a non-operating item. Non-GAAP EPS of $4.89 (up 18%, against roughly $4.72-$4.73 expected) is the better measure of core earnings growth [1][6]. Guidance also came in above expectations. Management guided fiscal Q2 revenue to $96.0-$97.1B and constant-currency Azure growth to 49-50%, against a Street forecast of about 45.1%, and said demand still exceeds supply [12]. Copilot daily users were reported up nearly 50% quarter over quarter [18]. On September 15, Microsoft raised its quarterly dividend 8% to $0.98 [2]. That works out to a yield of roughly 0.7%, and Morgan Stanley noted the raise was smaller than the company's five-year average increase of about 10% [2][14]. Valuation is moderate for the growth rate but not cheap. The trailing P/E is about 27-29x and the forward P/E about 25-26x; the forward figure is derived from a $20.01 fiscal-year EPS estimate [13][16][21]. The PEG ratio is 1.54 [21]. On trailing P/E, MSFT sits below Amazon (35x) and well above Alphabet (14x), with a 46.8% operating margin [16]. No sourced comparison to MSFT's own five-year multiple history was available [13][16][21]. The main counterweight is capital intensity. Q1 capex was about $39.4B in cash purchases of property and equipment, or $45.2B including finance leases. Free cash flow was reported at $18.6B, down about 27% year over year [5][11]. Management guided Q2 capex above $50B and calendar-year capex near $170-175B [5][11]. About three-quarters of that spending reportedly goes to short-lived CPUs and GPUs [18]. Q1 spending came in below plan partly because third-party capacity arrived late, so the lower figure may reflect timing rather than restraint [5][11]. Other cited risks: Microsoft Cloud gross margin trending toward about 65%, OpenAI at about 11% of revenue, and Windows OEM and Devices revenue down 22% [18]. Some GPU-as-a-service contracts expected in the December quarter have slipped into the second half of the fiscal year [6], and supply limits could cap reported growth even while they support pricing [12]. The stock's recent record also gives a cautious reader pause. MSFT closed at $523.00 on November 12, up only 2.82% over 52 weeks, inside a $349.20-$559.15 range [8]. It fell about 6.6% from its November 4 record close of $555.80 to roughly $519 in premarket trading on November 12 [20]. Coverage pointed to competitive pressure from Anthropic's Claude Sheets on Excel and to unconfirmed reports of a possible U.S. ban on Chinese data-center components, but no definitive cause was confirmed. Evercore does not yet see Claude Sheets as an Excel substitute [20]. StockInvest.us's quantitative model flags the stock as a 'Sell Candidate' [10]. The Wall Street view is strongly positive. S&P Global data covering 58 analysts shows 41 Strong Buy, 12 Buy, 5 Hold and no Sell ratings [7]. The average 12-month target is $636.12 and the median $631, about 21.6% and 20.7% above the $523 close, within a range of $440 (-15.9%) to $870 (+66.4%) [4][10]. The average target has risen about $63 since September 18 [4]. In the days before November 13, brokers reiterated their targets rather than changing them: Citi at $680, Piper Sandler and Stifel at $650, RBC at $640 and Evercore at $635 [15]. Morgan Stanley's target is reported both as $650 and as $600 [10][14][15]. The technical picture is mixed and depends on which source is used. One set of trackers shows the stock slightly above a 50-day average near $518.72 and about 18.6% above a 200-day average near $440.97, with the 50-day well above the 200-day [3]. Another source puts the short-term averages near $529-$531, above the price, and the 200-day at $459.34 [17]. RSI readings range from neutral (about 47-52) to near oversold (34.01 on November 11), so neither source shows an overbought condition [9][17]. Cited support levels are $514.95 and $507.73, and resistance levels $533.75 and $545.33, all from a lower-tier source [17][19]. The September 10 low of $486.00 is a deeper reference level [19]. The next named catalyst is Microsoft Ignite on November 17-20. Citi wants evidence there that Copilot is becoming an enterprise agent platform, and Morgan Stanley wants proof that Microsoft can serve AI demand more profitably [10]. In short, the supportive evidence is accelerating Azure growth, above-consensus guidance and broad analyst backing. The cautionary evidence is heavy and rising capex, lower free cash flow, margin pressure, concentration in OpenAI, and a stock that has done little over 52 weeks despite repeated earnings beats.

AMD logo

AMD

Nov 12, 2026

Advanced Micro Devices, Inc. · 8 days ago

AMD's Q3 2026 report (quarter ended September 26, 2026, reported November 3) set a revenue record of $13.377B, up 45% year over year and 16% sequentially [1][3]. Growth came almost entirely from Data Center, which rose 97% to a record $8.546B, about 63.9% of revenue [1][2][3]. Embedded rose 29% to $1.109B, while Gaming fell 40% to $773M [3]. Non-GAAP diluted EPS of $2.09 (+74% y/y) beat a consensus of about $1.94 [2][4]. Finding [1] names no one-time item behind the beat, but the reconciliation shows several that affect the two EPS lines differently [2][4]. GAAP diluted EPS of $1.46 absorbed a non-cash $1,097M (about $0.66/share) charge for the change in fair value of the customer warrant liability. GAAP was also helped by a $555M income-tax benefit and a $67M investment gain, and smaller items included $27M of acquisition costs and a $7M legal contingency. Non-GAAP excludes all of these and uses a 13% projected tax rate [4]. Neither headline EPS figure alone shows underlying earnings: the warrant charge pulls GAAP down and the tax benefit pushes it up [4]. On a non-GAAP basis, the sources do not attribute the beat to a one-time gain [1][2]. Q4 guidance of about $17B ±3% implies about 66% y/y and 27% sequential growth at the midpoint [6][7][10]. The OpenAI commitment to buy 6 GW of MI450 GPUs is the main forward revenue catalyst [6]. Most of the Street stays constructive. One count shows 45 of 56 ratings at Buy or Strong Buy, 11 Hold and 0 Sell, with a consensus target of $640.21 [8]. Other aggregators put the average between about $617 and $658.53, depending on the analyst set and snapshot date [8][12][15]. Recent targets include Citi at $800, Goldman reportedly at $700 (lower confidence), Piper Sandler at $650, Jefferies at $640, Wells Fargo at $615, Oppenheimer at $600 on a November 9 upgrade to Outperform, and DA Davidson at $600 [9][11][12]. The cautious case rests on cash quality, margins, dilution and valuation. Q3 free cash flow was only $554M, a 4% margin, against $4.678B for the first nine months [5]. Inventories rose to $11.463B from $7.920B at year-end 2025, and the inventory build used $3.0B of cash in the quarter [5][7]. That stockpile is a working-capital risk if the MI450 ramp slips [7]. Total debt rose to $7.079B from $3.226B after $4.726B of new issuance, though it sits against $15.776B of cash and short-term investments [5]. The Q4 non-GAAP gross-margin guide of about 55%, down from 56% in Q3, was blamed for the post-earnings fade: shares fell from a ~$523 premarket high on November 4 to close near $489 [6][10]. The OpenAI warrant covers up to 160 million shares that vest on milestones. That makes the same deal both a revenue catalyst and a source of dilution and GAAP earnings volatility, and Q3's $1,097M charge shows the volatility has already started [4][6]. Not all post-earnings sell-side moves were raises. Mizuho cut its target to $610 from $705 while keeping Outperform, and JPMorgan stayed Neutral at $575 [11][12]. 24/7 Wall St.'s own model target of $505.37 ($404.58 to $681.35 bear-to-bull) sits below the analyst consensus [22]. Valuation looks stretched against both the peer and AMD's own history, though the forward multiple is less extreme. At the November 11 close of $552.90, StockAnalysis shows a trailing P/E of 119.8, a forward P/E of 36.7, EV/EBITDA of 81.9, EV/Sales of 20.1 and price-to-book of 12.35, on a market cap of about $906.8B [13]. Against NVIDIA on the same date (trailing P/E 22.0, forward P/E 14.4, EV/EBITDA 20.7, trailing FCF $127.0B against AMD's $7.06B), AMD trades at a large premium [14]. Against its own FY2021 to FY2025 year-end range, EV/EBITDA of 81.9 is above every year (18.7 to 61.0) and price-to-book is well above the FY2022 to FY2025 range (1.91 to 5.56). The higher book multiple partly reflects the reset of book value by the Xilinx acquisition [19]. The forward P/E of 36.7, however, sits mid-range against AMD's own 20.3 to 46.6 history and slightly below the FY2025 year-end level of 38.7 [19]. Because GAAP amortization and the warrant charge inflate the trailing multiple, the forward multiple is the more meaningful comparison [4][21]. AMD pays no dividend and bought back no stock in Q3 [13]. Technically, the stock was up 126.6% over 52 weeks [15] and about 133.6% year to date as of November 9, against about 9.9% for the S&P 500 [16]. It was still roughly 21–24% below its October 52-week high of $658.52 [16][21], and its 5-year beta is 2.54 [15]. After the November 5–6 selloff, the price fell to about $432 on Tradingpedia's 24-hour feed (a $449.04 Nasdaq close on November 6) [17][22]. Readings were oversold or near oversold: RSI 35.16 per Tradingpedia, about 29.7 at the November 5 close per JournalArta, and the price below the lower Bollinger Band [17]. By November 11–12, RSI had recovered to a neutral 48.6–53.6 [15][23]. Support levels cited are about $483.90, $449.04, $395–404 and $358.55. Resistance levels are about $504.80, $515–523, $538.05, $566.42 and $658.52 [18]. The balance of evidence: strong, Data Center-led growth and a large Q4 guide on one side. On the other: thin Q3 free cash flow, a heavy inventory build, a slight margin step-down, warrant dilution and premium multiples, all of which leave the outcome tied to on-time MI450 execution.

Crypto

Crypto examples

The same pipeline, tuned for crypto: tokenomics, on-chain health, technicals, and regulatory risk.

HYPE logo

HYPE

Nov 4, 2026

Hyperliquid · 16 days ago

Valuation and tokenomics present the central tension. HYPE trades near $84 with a circulating market cap of roughly $20.1 billion and an FDV of about $80 billion, because only 239.4 million of the 1 billion max supply (23.9%) is circulating, producing a ~4.0x FDV-to-market-cap ratio [4][6][7][10]. Against peer BNB, HYPE's circulating cap is about 22% of BNB's $91.3 billion while its FDV is about 88% of BNB's, underscoring a much larger locked-supply overhang [8]. Core contributors hold 23.80% of genesis supply and unlock at roughly 9.9 million HYPE per month through 2027, with the next tranche dated November 6, 2026 [13][15][17]; sources conflict on the size of that tranche, with one report describing it as trimmed to 180,000 HYPE (~$15.7M) from 9.92 million scheduled [12]. Offsetting this, the Assistance Fund routes 97-99% of protocol fees into open-market buybacks that have removed about 49.87 million HYPE (~5% of max supply) at a recent pace of roughly 591,000 HYPE per month, well below the monthly contributor unlock [17][20]. The fee base behind those buybacks is substantial: $84.78 million in 30-day fees and roughly $713 million in trailing-12-month revenue [9]. Staking yields about 2.24-2.37% with 7-day unstaking, and roughly 439 million HYPE is staked, a figure that exceeds circulating supply because vesting allocations can stake [14][19]. On network health and the regulatory picture, the evidence is mixed. DefiLlama reports Hyperliquid L1 TVL of about $2.54 billion by one measure and $8.07 billion by a broader one, and 24h active addresses of 19,111, but no consistent active-address trend series was available [16][21]. HIP-3 builder perps have scaled to 484 markets with cumulative volume above $548 billion, yet a single deployer, Trade.xyz, holds over 90% of HIP-3 open interest, and the core node code is not published as source [23][25]. Foundation-linked validators controlled about 48.9% of stake as of June 2026 [22]. The November 3 CFTC approval of U.S. equity perpetuals lifted HYPE about 2% and Hyperliquid has named Kraken parent Payward, via Bitnomial, as its planned first CFTC-regulated HIP-3 deployer, though that remains on testnet pending approval, Hyperliquid itself still blocks U.S. users, and Cboe, Citadel Securities and the Healthy Markets Association have sued to challenge the CFTC ruling [1][5]. Technically, HYPE sits slightly below its 50-day average but 20-25% above its 200-day average, with neutral RSI readings of roughly 41-55, about 14% below the $97.96 all-time high set September 23 [2][6][11]. Support clusters at $78.4 and the $75.7-$76 October low with deeper levels at $67.6 and $61.2, while resistance stacks at $85-$88, $92-$94.6 and $97.96 [3]. Near-term pressure includes $109 million of whale sales on October 31, a reported $224 million Paradigm unstake, and $612 million of leveraged longs clustered just below $86 [12]. Analysts are split: a potential head-and-shoulders targets $59-$62 if $76-$78 breaks, while a rebound scenario projects $112-$116; neither is confirmed [24]. Longer-term, HYPE is up roughly 99% over six months and 106-109% over twelve months, though aggregators disagree on exact figures [18].

BTC logo

BTC

Jul 1, 2026

Bitcoin · 142 days ago

Where valuation stands today: Bitcoin trades around $58,300–$58,600 with a market cap near $1.18 trillion [1], after falling roughly 20% in June 2026 (opening near $73,500, closing near $58,500) [5] and roughly 43.7% over the trailing 12 months [12] — well below the 2025 all-time high near $126K [11]. Unlike equities, BTC has no earnings-based valuation; its 'fundamentals' are supply/issuance, network security, and flows. The proximate drivers of the drawdown were record spot-ETF outflows (a ~$3.4B single-week record, the largest since the January 2024 launch, with ~$4.5B redeemed across June — the worst month on record, including a 13-day outflow streak of ~$4.4B) [4][6], a hawkish Fed repricing that pushed the 10-year Treasury yield up ~18bps to ~4.82% and rate cuts toward 2027 [10], and profit-taking as a ~34% two-month rally that peaked near $74,500 in late May reversed ~22% [9]. Geopolitical stress (the reported 103rd day of the U.S.-Israel–Iran conflict and an oil-price spike) added risk-off pressure, though on a single, low-confidence source [15].

SOL logo

SOL

Jul 1, 2026

Solana · 142 days ago

Valuation and tokenomics: As of 2026-07-01 SOL trades near $73 (aggregator band ~$72.69–$74.61) for a market cap of ~$42.7B and FDV of ~$46.3B, ranking #7 [1][4][5]. With ~580.9M of ~629.5M tokens circulating (~92.3%) and an uncapped, inflationary supply, the market-cap-to-FDV ratio sits near 0.92 — only ~8% overhang, and most future dilution comes from ongoing ~3.77% inflation (disinflating 15%/yr from an 8% start toward a 1.5% floor) rather than large unlock cliffs [3][6][7][9][15]. The FTX/Alameda estate's residual ~5M locked SOL is under ~1% of float, so the unlock overhang is modest [8]. About 67.9% of supply (~427M SOL) is staked at ~5.5–6.5% APY, and SOL's market cap is roughly 22% of Ethereum's ~$190.1B [2][3][22]. Note one same-source snapshot lists a slightly higher $43.4B cap / $47.0B FDV, illustrating intra-day aggregator variance [12]. Bull case (network health, catalysts, technicals): Solana posts strong usage — a record ~2.1M daily active addresses and ~238.5M daily transactions at the highest throughput among major L1s (~$0.00025/tx), SOL-denominated TVL at an all-time high above 80M SOL in Feb 2026, a record ~11,534 new developers, and 2,100+ active dApps [16][17][19]. Institutional access is the marquee catalyst: U.S. spot SOL ETFs launched ~Oct 2025 (BSOL, FSOL) with ~$1.3–1.45B cumulative inflows, Morgan Stanley filings in Jan 2026, and Alpenglow/Firedancer upgrades cited as supportive, with SEC deadlines mid-to-late 2026 [13][20]. Technically the posture is mildly bullish/neutral: spot sits fractionally above the 50-day (~$72.12) and 200-day (~$71.62) averages, RSI(14) reads a neutral ~52–62, and SOL is up ~50.3% over 12 months [5][11][21]. Bear case, key risks, and what would change the read: The core bear signal is weak value capture — of ~$10M daily ecosystem fees only ~$100k accrues to the protocol, and monthly Real Economic Value collapsed ~95% from ~$550M (Jan 2025) to ~$23.5M (Dec 2025), suggesting much 2025 activity was speculative [18]. USD DeFi TVL fell from ~$9B to ~$5.5–6B after the April 2026 Drift exploit, and SOL remains ~74.6% below its $293.31 ATH (Jan 2025) [11][17]. The proposed SIMD-0550 (not enacted) could accelerate disinflation and cut modeled staking yields to ~4.3% in year one and ~2.25% by year three, and ~600k SOL flowing to exchanges leaves holder-flow direction genuinely mixed against concurrent whale accumulation [14][24]; regulatory outcomes (CLARITY/GENIUS Act, pending SEC decisions) remain open [20]. On the balance point: a weekly close above $73.50 opens $75–$80, while losing $71.50 exposes $68, then $64 and the $60 June floor — with sustained ETF inflows vs. outflows the specific factor most likely to flip the balanced read [10][13][23].

DOGE logo

DOGE

Jun 7, 2026

Dogecoin · 166 days ago

Price/technical state: As of June 7, 2026, DOGE trades around $0.083-$0.085 with a market cap of roughly $13-14.3B (rank #10-11) and ~$0.68-0.76B in 24h volume. The picture is bearish in the near term. DOGE is down ~16% over 7 days and ~23-30% over 30 days, having broken a descending channel near June 4 amid a sector-wide memecoin selloff (BONK, PEPE, SHIB also fell). Six-month return is roughly -40% and the 12-month return is contested (~-52% to -63% on some trackers, though CoinGecko shows +54% on a 1y basis depending on the start date), reflecting how much DOGE has retraced from its late-2024/early-2025 highs. Price sits well below both its 50-day MA (~$0.10-0.11) and 200-day MA, a bearish alignment, and RSI(14) is near 30 (oversold). Near-term support clusters around $0.080-0.082 with resistance near $0.095-0.105. Bull case: DOGE retains deep liquidity, the strongest meme-coin brand, and is now nearly 4x Shiba Inu's market cap (~$13-14B vs ~$3.6B) with far higher turnover. In March 2026 the SEC and CFTC jointly classified DOGE as a digital commodity (one of 16 named assets), removing the main legal barrier to spot ETFs and shifting oversight toward the lighter-touch CFTC. Multiple U.S. spot/derivative ETF wrappers now exist (REX-Osprey DOJE since Sept 2025; 21Shares TDOG on Nasdaq since Jan 2026, 0.50% fee; Grayscale and Bitwise products auto-launched in late 2025), giving regulated access. Payments adoption has incrementally improved: Tesla reinstated DOGE for merchandise/Cybertruck accessories in 2026, the Dallas Mavericks accept it, and Musk's X Money launch is a sentiment driver. Whale wallets reached multi-year/all-time highs in 2026 (e.g., ~108B+ DOGE held by the largest cohort per Santiment), framed by some as professional accumulation. Tokenomics are disinflationary: a FIXED 5B DOGE/year tail emission (10,000 DOGE/block, ~1-min blocks) means the inflation rate keeps falling (~3.2% now, toward ~2% by ~2040), and ~70%+ of security comes free via merged mining with Litecoin. Bear case/risks: DOGE has no max supply and perpetual issuance, so demand must absorb ~5B new coins every year indefinitely. ETF demand has been tiny: combined U.S. DOGE-ETF AUM was only ~$14.7M as of mid-May 2026 (DOJE ~$18-20M, TDOG ~$4M), a fraction of BTC/ETH ETF scale, and several sessions in late May 2026 saw zero daily flows. Ownership is extremely concentrated: the top 100 addresses hold ~66-67% of supply, the top 10 ~45-60%, and the single largest wallet (Robinhood's cold wallet) holds ~27.2B DOGE, ~18% of supply (the famous ~28-30B address; it is custodial user funds, not one whale). On-chain usage is modest relative to market cap (~30,000 active addresses/day, ~22,000 tx/day, ~$110M transferred), with most volume speculative; developer activity and native utility remain low versus Ethereum/Solana. DOGE stays heavily dependent on Musk/X headlines and broad memecoin sentiment, making it prone to sharp reversals. This report is informational only and is not a buy or sell recommendation.

ETH logo

ETH

Jun 7, 2026

Ethereum · 166 days ago

As of June 7, 2026, Ethereum (ETH) trades around $1,628 with a market cap of roughly $190-197 billion, the #2 crypto asset behind Bitcoin. The defining fact of the past year is severe price weakness: ETH is down ~65-67% from its August 24, 2025 all-time high near $4,950, having bottomed around $1,390-$1,735 in late May/early June 2026 before a sharp oversold bounce (+~19% over 7 days, +~30% over 30 days). It has also badly underperformed Bitcoin, with the ETH/BTC market-cap ratio compressed to ~0.14-0.15 and ETH dominance near 8.9% versus BTC's ~56%. Technically the bounce lifted ETH back above its 50-day moving average (~$1,590) but it remains below the 200-day (~$1,815) in a confirmed death-cross structure; RSI(14) has recovered from oversold (~33 on June 3) to neutral (~58 on June 7). Support sits at $1,600-$1,650 (floor cluster ~$1,400); resistance at $1,800-$1,820, then $2,000. The bull case rests on fundamentals and regulatory clarity. On March 17, 2026, the SEC and CFTC issued a binding joint interpretive release classifying ETH as a 'digital commodity' (not a security) under CFTC oversight, and explicitly held that staking is not a securities transaction — unlocking staking-enabled spot ETH ETFs. Cumulative U.S. spot-ETH-ETF net inflows since launch stand near $11-12B (BlackRock's ETHA ~47% of flows). Staking hit a record ~39.5M ETH (~32% of supply, ~1.1M validators) at a ~2.9-3.3% yield, with a large validator entry queue and a near-empty exit queue signaling structural demand to lock up supply. The network is the largest by almost every measure: ~$45.5B L1 DeFi TVL (still ~53% of all DeFi), the largest developer base (~31,000 builders), and active addresses near multi-year highs (~586-590k/day). The technical roadmap is executing — Fusaka (PeerDAS, EIP-7594) went live December 3, 2025, with Glamsterdam targeted for H1 2026. The bear case is a value-accrual problem. Post-Dencun (March 2024), activity and fees migrated to Layer-2s, collapsing mainnet fee revenue (daily L1 fees down ~40% YoY) and the EIP-1559 burn, so ETH is now mildly inflationary (~+0.2% net annual issuance) rather than 'ultrasound money.' L2s capture most of the economic value while paying Ethereum only a small blob fee (e.g., Base earned ~$94M profit but paid ~$4.9M in blob fees), and Vitalik Buterin has conceded the original L2 vision 'no longer makes sense' — restoring ETH's value capture is the central open question. Competition is intensifying (Solana DEX volumes have at times exceeded Ethereum L1), DeFi dominance has slipped from ~63% to ~53%, and security risk remains live — 2026 DeFi/bridge exploits exceeded $750M by April, led by the ~$292M Kelp DAO bridge hack (April 18, 2026, attributed to Lazarus Group). On balance, ETH is the dominant, now-regulated smart-contract settlement layer trading ~65% off its highs, but its 6-24 month re-rating depends on whether L2 scaling translates into measurable ETH value accrual rather than cannibalizing it.

ADA logo

ADA

Jun 7, 2026

Cardano · 166 days ago

Cardano (ADA) trades near $0.16-0.17 in early June 2026 (CoinGecko ~$0.165, market cap ~$6.1B, rank #18), down roughly 60-63% over the trailing 12 months and well off its 2025 highs (it began 2026 near $0.40 and fell through $0.30 in March and below $0.20 in late May/early June). The technical picture is firmly bearish on trend but stretched on momentum: ADA sits far below both its 50-day (~$0.24-0.25) and 200-day (~$0.31-0.42, source-dependent) moving averages, a classic downtrend, while the 14-day RSI prints deeply oversold (readings of ~12-18 on some trackers versus a neutral ~48 on others, so treat the exact figure as contested). Near-term support sits around $0.14-0.15 with resistance near $0.23-0.26; a recent bounce of ~5-6% in 24h came off oversold conditions rather than a confirmed trend reversal. The bull case rests on technology and structural catalysts rather than current usage. Cardano remains one of the most active blockchains by developer output (reports of ~680 weekly GitHub commits and thousands across teams), with a near-term Plutus upgrade (V11 / Van Rossem hard fork expected late June 2026 adding BLS12-381 primitives for ZK use cases) and scaling work via Hydra (live for micro-transactions) and Ouroboros Leios (testnet, mainnet targeted end-2026, aiming for large throughput gains toward 1,000+ TPS). On-chain activity has actually firmed despite weak price: daily active addresses rebounded to multi-month highs (~17,500, a ~14% jump from late May) and large-wallet (whale) cohorts accumulated. The regulatory tailwind is concrete: CME ADA futures launched Feb 9, 2026, starting a six-month clock under the SEC's Sept-2025 generic listing standards that makes ADA eligible for a streamlined spot-ETF pathway around Aug 9, 2026, with a possible decision by ~late Oct 2026; Grayscale (GADA), Bitwise and Canary are among issuers positioning, and futures ETFs are already live. A ~$1B+ treasury (funded by ~20% of epoch emissions) and a working on-chain governance system add to the structural argument. The bear case is the gap between valuation and adoption. Cardano's DeFi TVL is only roughly $120-150M (sources range widely, ~$88M to ~$150M; some cite a broader ~$550M ecosystem figure), a small fraction of Ethereum's ~$71B and ~12% of Solana's ~$9B, leaving an extreme market-cap-to-TVL ratio (cited as high as ~66x) that critics read as a structural valuation ceiling. Stablecoin liquidity, while growing fast (~$47-55M total, now USDC-led), is tiny in absolute terms. The Plutus/eUTxO/Haskell development model limits how quickly third-party protocols ship, feeding a long-running 'always one upgrade away' critique after a ~90% drawdown from the 2021 all-time high. Governance risk is now visible too: in late May 2026 a DRep treasury vote to fund the 2026 Cardano Summit failed (65.21% yes vs the 66.67% supermajority required), cancelling the flagship event and denting sentiment. Staking yield is modest (~2.8-4.5% APY, ~58-63% of supply staked). ETF approval, Leios delivery and DeFi traction are all unproven catalysts, and ADA's regulatory classification (commodity vs the SEC's prior security allegations) is not fully settled. This report is informational only and is not a buy, sell, or hold recommendation.

Full list

All 49 reports

Every stock and crypto report we have published, newest first.

Stocks

Crypto

Run one on any ticker

Pick a stock, add your own focus, and get the same source-verified analysis.